Core Thesis - Bristol-Myers Squibb Company (BMY) is viewed positively due to its strong dividend history, diversified product portfolio, and potential for long-term growth [1][5]. Financial Performance - As of March 26th, BMY's share price was $59.43, with trailing and forward P/E ratios of 16.61 and 9.20 respectively [1]. - In 2024, BMY reported $48.3 billion in revenue, reflecting a 7% year-over-year increase, with non-GAAP EPS of $1.15 [3]. Dividend and Cash Flow - The company has a 17-year streak of consecutive dividend increases, currently yielding 4.63% with an annual payout of $2.52 per share, supported by strong free cash flow and profitability [2]. Product Portfolio and Growth Potential - Established products like Opdivo and Eliquis provide stable revenues, while growth drugs such as Reblozyl and Breyanzi, along with late-stage candidates like milvexian and admilparant, offer substantial upside potential [3]. - The company plans over ten new product launches by 2030, indicating a strong commitment to innovation [4]. Strategic Partnerships and Market Position - Strategic partnerships, including collaborations with BioNTech and AI-driven initiatives, enhance innovation and strengthen BMY's pipeline [3][4]. - Institutional backing from major firms like Vanguard, BlackRock, and State Street reflects confidence in BMY's strategy and financial stability [4]. Analyst Consensus - Analysts maintain a "Buy" consensus with an average 12-month price target of $57.64, indicating moderate upside potential [5].

Core Insights - Gilead Sciences, Inc. (GILD) is enhancing its external innovation strategy through targeted acquisitions to diversify its pipeline beyond its leading HIV franchise [1] Group 1: Acquisitions and Strategic Moves - The acquisition of Ouro Medicines introduces OM336 (gamgertamig), a clinical-stage bispecific T-cell engager, to Gilead's inflammation portfolio, valued at $1.675 billion upfront with potential milestones of up to $500 million [2] - Gilead's acquisition of Arcellx for approximately $7.8 billion focuses on anitocabtagene autoleucel (anito-cel), a late-stage CAR-T therapy for relapsed or refractory multiple myeloma, with a U.S. regulatory decision expected by December 2026 [3] - The Arcellx deal allows Gilead to consolidate full economic rights to anito-cel, enhancing long-term margin potential and value capture by eliminating prior profit-sharing and royalty obligations [4] Group 2: Financial Implications and Market Position - These acquisitions indicate a strategic shift towards higher-growth therapeutic areas such as oncology and immunology, reducing reliance on HIV revenues from blockbuster products like Biktarvy and Descovy [5] - Management anticipates that the Arcellx transaction will be earnings accretive by 2028, reinforcing the long-term financial rationale for these acquisitions [5] Group 3: Competitive Landscape - Gilead faces increasing competition in the cell therapy segment, particularly from Bristol Myers (BMY) and Novartis (NVS), which have strong CAR-T therapy portfolios [6][7] - BMY's Breyanzi surpassed $1 billion in annualized sales in 2025, while NVS's Kymriah recorded sales of $381 million in 2025, down 14% from 2024 due to competitive pressures [8][9] Group 4: Stock Performance and Estimates - GILD shares have increased by 11.5% year to date, outperforming the industry growth of 1.6% [13] - GILD's shares currently trade at a price/earnings ratio of 15.4x forward earnings, higher than its mean of 11.37x but lower than the large-cap pharma industry average of 16.99x [14] - The bottom-line estimate for 2026 has risen to $8.66 from $8.63 over the past 30 days, while the estimate for 2027 has increased to $9.63 from $9.59 [15]

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]

Core Insights - Bristol Myers Squibb (BMY) reported positive interim results from the late-stage SUCCESSOR-2 study, evaluating mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma (RRMM) patients [1][3] Group 1: Study Results - The SUCCESSOR-2 trial demonstrated that oral mezigdomide combined with carfilzomib and dexamethasone significantly improved progression-free survival compared to carfilzomib and dexamethasone alone in RRMM patients [3][10] - This study marks the first positive phase III trial for mezigdomide and the second successful phase III study for BMY's CELMoD program, reinforcing confidence in the company's targeted protein degradation platform [4][10] Group 2: Market Context - Despite advancements in treatment, multiple myeloma remains incurable, leading to strong demand for new therapies, particularly those effective after prior treatments [5] - Mezigdomide is designed to be more effective than earlier immunomodulatory drugs, potentially offering a convenient oral treatment option for patients previously treated with therapies like anti-CD38 antibodies and lenalidomide [6] Group 3: Company Strategy - BMY is looking to diversify its portfolio as its legacy drugs, such as Revlimid, face generic competition, which pressures revenue growth [7] - The successful development of mezigdomide could significantly boost the company's position in the market [7][10] - BMY's targeted protein degradation platform includes various investigational approaches aimed at tackling disease-driving proteins previously considered difficult to target [8] Group 4: Future Prospects - Patients in the SUCCESSOR-2 study will continue to be monitored for overall survival and long-term safety outcomes, with data to be presented at future medical meetings [4] - Mezigdomide is also being evaluated in other combinations in ongoing phase III studies, indicating a robust pipeline for BMY [9]

Core Insights - Bristol Myers Squibb (BMY) received FDA approval for a label expansion of its psoriasis drug, Sotyktu (deucravacitinib), making it the first and only TYK2 inhibitor approved for treating adults with active psoriatic arthritis (PsA) [1][6] Drug Approval and Efficacy - The FDA's approval was based on positive results from the POETYK PsA-1 and POETYK PsA-2 studies, where Sotyktu significantly improved disease activity compared to placebo at week 16 [2] - In the PsA-1 study, 54% of patients on Sotyktu achieved an ACR20 response compared to 34% for placebo, while the PsA-2 trial showed a 54% response rate versus 39% for placebo [3] Sales Performance - Sotyktu generated sales of $291 million in 2025, reflecting a 19% increase from 2024, with the new label expansion expected to further enhance sales [7][6] Company Performance and Strategy - Bristol Myers Squibb demonstrated resilient performance in 2025, supported by key growth drivers like Opdivo, Opdualag, and others, which helped stabilize revenue despite generic erosion in its legacy portfolio [8] - The company is focusing on diversifying its portfolio through potential approvals of new drugs and label expansions for existing drugs [8] Pipeline and Future Prospects - Bristol Myers has a pipeline that includes three clinical-stage and two phase I-ready programs targeting key immune pathways, with leading assets like afimetoran and BMS-986322 showing promise [10] - The collaboration with Bain Capital to create a new biopharmaceutical company aims to develop therapies for autoimmune diseases, starting with five immunology assets and a $300 million investment [9] Competitive Landscape - Sotyktu faces competition from Amgen's Otezla, which generated $2.26 billion in sales in 2025 [11]

Core Insights - Bristol Myers Squibb (BMY) shares have increased by 11.4% over the past month, outperforming the industry growth of 5% and also surpassing the sector and S&P 500 performance during the same period [1][2] Group 1: Financial Performance - BMY's robust fourth-quarter results are attributed to the strength of its growth portfolio and improved investor sentiment [1] - The company's growth portfolio accounted for 55% of total revenues in 2025, driven by key brands such as Opdivo, Reblozyl, Breyanzi, and Camzyos [5][8] - The legacy portfolio faced a 15% revenue decline in 2025 due to generic competition, generating 45% of total revenues ($48.2 billion) [12] Group 2: Growth Drivers - The immuno-oncology (IO) portfolio, particularly the drug Opdivo, remains a top revenue generator, with strong sales driven by label expansions and market share growth [6] - Reblozyl, co-developed with Merck, has annualized sales exceeding $2 billion, while Breyanzi sales surpassed a $1 billion annualized run rate [9] - The cardiovascular drug Camzyos has also shown strong performance, with initial sales of $155 million in 2025 [10] Group 3: Pipeline and Future Prospects - BMY is focused on diversifying its pipeline, with six key candidates expected to report top-line registrational data in the second half of the year [14] - The company has made strategic acquisitions, including Orbital Therapeutics, to enhance its pipeline [15] - BMY is targeting $2 billion in annual cost savings by 2027, with approximately $1 billion achieved in 2025 [21] Group 4: Valuation and Estimates - BMY shares currently trade at a price/earnings ratio of 10.05x forward earnings, which is higher than its historical mean of 8.46x but lower than the large-cap pharma industry's average of 18.70x [18] - The Zacks Consensus Estimate for 2026 EPS has increased to $6.24 from $6.08, while the estimate for 2027 has risen to $6.05 from $5.88 [19]

Core Insights - The company delivered strong performance in 2025, with good momentum heading into 2026, particularly from its growth portfolio [1] - Key products such as Reblozyl, Breyanzi, and Camzyos performed well and are expected to continue contributing to growth [1] - The company is in the second year of launches for Cobenfy and Opdivo Qvantig, which will also support growth [1] - There are headwinds due to the presence of generics for Revlimid and Pomalyst in the market, impacting the legacy portfolio [1] - Significant growth is anticipated for Eliquis, with expectations of double-digit growth this year [2]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13][14] Market Data and Key Metrics Changes - The company expects U.S. Breyanzi net revenue guidance for 2026 to be between $825 million and $850 million, with total global revenue projected at $875 million to $900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million to $190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRIUMVI, citing strong patient persistence and physician confidence as key drivers [30][36] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in the company's long-term outlook [10][24] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS, enhancing the company's presence in the community [11][15] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [27][28] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change in their framework [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [34][36] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by both patients and centers [70][71]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved an operating income of $123 million for the year, with a net income of $447.2 million, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [22][25] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13] Market Data and Key Metrics Changes - The company expects full-year U.S. Breyanzi net revenue guidance of $825 million-$850 million for 2026, with total global revenue projected at $875 million-$900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million-$190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in generating positive cash flow in 2026 and beyond, highlighting the company's financial flexibility within the biotech sector [9] - The management team emphasized the importance of building a strong presence in the MS community and supporting patients beyond just commercializing BRIUMVI [11] Other Important Information - The company completed its first $100 million share repurchase program and authorized an additional $100 million, indicating confidence in its long-term outlook [23] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS [10] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain share in the IV segment and are not seeing decreases in switches from Ocrevus to BRIUMVI, with strong momentum across both private practice and academic centers [27][29] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence among existing patients, contributing to continued growth [35][38] Question: Incremental investments for sub-Q launch - Management indicated that the overlap between the current field force for IV and sub-Q is about 80%, suggesting minimal incremental costs for the sub-Q launch [42][47] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance convenience for patients and could lead to market share gains [70][71] Question: Early metrics from DTC launch and Next in MS program - Engagement metrics from the Next in MS initiative have exceeded expectations, with positive feedback from customers and advocacy groups [75]

Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to acquire Arcellx (ACLX) for $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion, enhancing Gilead's position in cell therapy [1][8] Acquisition Details - The acquisition focuses on anito-cel, a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma, which has demonstrated deep and durable responses with a manageable safety profile [4][11] - Gilead's subsidiary Kite Pharma already collaborates with Arcellx to co-develop anito-cel, indicating a strategic alignment between the two companies [2][11] - The deal includes a tender offer for all remaining Arcellx shares at a 68% premium to the 30-day volume-weighted average share price as of February 20, 2026 [9] Financial Implications - The acquisition is expected to be accretive to Gilead's earnings from 2028, strengthening its oncology and cell therapy portfolio [10][11] - Gilead currently holds approximately 11.5% of Arcellx's outstanding shares, which will be fully acquired through this transaction [9] Strategic Rationale - The acquisition allows Gilead to gain full control of anito-cel, streamlining development and commercialization processes, thereby enhancing long-term margin potential [11] - Gilead aims to diversify its revenue base and ramp up its oncology franchise, which has been under pressure [12] Market Context - Gilead anticipates ongoing competitive pressure in the cell therapies market, particularly from new entrants and established players like Bristol Myers (BMY), which has a strong cell-therapy portfolio [13] - The addition of anito-cel is expected to help Gilead offset declines in its existing cell therapy business [13]